Pooled analysis of 24 adults and children with KMT2Ar, NPM1m, or NUP98r acute leukemia who resumed revumenib post-transplant shows favorable ...
ORR and 70% CRc in venetoclax-naïve and 48% ORR and 24% CRc in venetoclax-experienced patients at the recommended 600 mg once-daily dose –– ...
A new study published in Nature Communications shows that human glial progenitor cells are a promising and safe cell product ...
The ASCERTAIN V clinical trial demonstrated that an all-oral drug combination for older patients with acute myeloid leukemia ...
Persistent viral infections pose a unique challenge to the immune system. Prolonged antigen exposure drives T cells into a state of exhaustion — a ...
Survival outcomes were favorable post-ASCT, with 90% 1- and 2-year OS, 82% 1-year EFS, and low nonrelapse mortality (4%), in a cohort enriched for KMT2Ar AML. Landmark comparisons suggested reduced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results